Safety and tolerability (adverse events; biochemical, hematological and urine analysis tests; vital signs, 12-lead ECG, physical examination) 3 Months [clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa]

Safety and tolerability (adverse events; biochemical, hematological and urine analysis tests; vital signs, 12-lead ECG, physical examination) 3 Months [clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa]

Dose 1
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa
A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects [clinicaltrials:NCT00454233]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability (adverse events; biochemical, hematological and urine analysis tests; vital signs, 12-lead ECG, physical examination) 3 Months [clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa]

Dose 1
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa
Bio2RDF identifier
e7ed3f507a5abeb83bf3c6e039a20bfa
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability (adver ...... ead ECG, physical examination)
time frame [clinicaltrials_vocabulary:time-frame]
description
identifier
clinicaltrials_resource:e7ed3f507a5abeb83bf3c6e039a20bfa
title
Safety and tolerability (adver ...... physical examination) 3 Months
@en
inDataset
type
label
Safety and tolerability (adver ...... d3f507a5abeb83bf3c6e039a20bfa]
@en